Eli Lilly Announces Global C-Suite Changes, New Leadership in China
US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio...
China’s Policy Shifts Medical Device Procurement Toward Domestic Products
Local government policies in China have begun to direct public hospitals to prioritize the procurement...
Antengene Expands to Australia with New Melbourne Office
China-based biotech firm Antengene (HKG: 6996) announced the opening of its new office in Melbourne,...
Great Bay Bio Completes USD 15M Pre-Series B Financing to Advance AI Bioprocessing Platforms
Great Bay Bio (GBB), a Hong Kong-based biotechnology firm, announced the completion of a USD...
Zhonghong Pulin Partners with Shanghai Pharma for Logistics and Distribution
China-based Zhonghong Pulin Medical Product Co., Ltd (SHE: 300981) has entered into a partnership with...
Suzhou Jade Biomedical Secures USD 10 Million Series B Financing
China-based Suzhou Jade Biomedical Co., Ltd reportedly raised USD 10 million in a Series B...
Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding
Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD...
Luye Life Sciences Partners with Uzbekistan to Establish Vaccine Center
China-based Luye Life Sciences Group has struck a partnership with the Ministry of Innovation and...
Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion
Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...
Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance
China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized...
Bide Pharmatech Set for IPO on Shanghai’s STAR Market
Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make...
NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for...
Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment
Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...
Guangdong Launches Free HPV Vaccination Program for School-aged Girls
Guangdong province has rolled out a free HPV vaccination program this month, aimed at improving...
Suzhou Zelgen Completes Phase II Study of Jakinib for Ankylosing Spondylitis
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the successful completion of a multi-center, randomized...
Hubei Province Proposes National TCM Patent Medicine Procurement Alliance
The Healthcare Security Administration of Hubei Province has proposed the establishment of a national traditional...
Buchang Pharmaceuticals Gains NMPA Approval for BC008-1A Clinical Study
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced that it has received approval from...
CDE Prioritizes Review of Pearl Bio’s Breatinib for NSCLC Treatment
The Center for Drug Evaluation (CDE) website indicates that Beijing Pearl Biotechnology Co., Ltd’s APL-101/PLB1001...
Jiangsu Hengrui Medicine Gains NMPA Approval for HRS-6209 Clinical Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
I-Mab’s Lemzoparlimab Gains CDE Approval for HR-MDS Phase III Trial
China-based I-Mab (NASDAQ: IMAB) announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting...